Epitalon, Pinealon, and Cortagen: Khavinson Bioregulator Family

The Khavinson short peptide bioregulators represent a distinctive strand of aging and neuroprotection research originating from the St. Petersburg Institute of Bioregulation and Gerontology. Over several decades, Vladimir Khavinson and colleagues developed a library of ultrashort synthetic peptides — each two to four amino acids in length — derived from specific tissue extracts and hypothesized to act on gene expression in a tissue-selective manner. Among the most studied members of this family are Epitalon, Pinealon, and Cortagen, three compounds that share a common mechanistic hypothesis but differ substantially in their target tissues, primary research endpoints, and the body of evidence that has accumulated around them.

This article examines each compound individually, compares their pharmacological profiles side-by-side, and outlines how researchers have differentiated their applications in preclinical models.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Epitalon: mechanism and evidence base

Epitalon (also rendered as Epithalon or Epithalamin) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly and molecular formula C₁₄H₂₂N₄O₉ (MW 390.4 g/mol). It was derived from pineal gland extract and has been the subject of research primarily focused on telomere biology and the neuroendocrine regulation of aging.

The central mechanistic hypothesis for Epitalon concerns telomerase activation. Laboratory studies have demonstrated that the compound increases hTERT mRNA expression — the catalytic subunit of telomerase — and raises telomerase enzyme activity in treated cells. In normal somatic cells, this results in measurable telomere length extension. Research also identified a secondary mechanism in cancer cell lines, where telomere extension occurred via ALT (Alternative Lengthening of Telomeres) activation rather than through telomerase upregulation, suggesting the compound's effects on telomere maintenance may be pathway-dependent and cell-type specific (PMID 41240216).

Beyond telomere biology, Epitalon has been studied for its proposed interaction with the hypothalamic-pituitary-pineal axis. Animal model research indicated possible effects on circadian rhythm regulation and melatonin production cycles. Preliminary in-vitro data also suggested antioxidant properties via modulation of reactive oxygen species pathways in cellular models.

Regulatory status: Epitalon is not approved by the FDA or EMA as a therapeutic agent. It carries approved status in Russia for research purposes and is classified as under review for 503A compounding in the United States.

PMID 41240216 — "Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity" (2025). https://doi.org/10.1023/A:1016027606368

Pinealon: mechanism and evidence base

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg. As a Khavinson-family bioregulator, it is hypothesized to exert effects through direct interaction with DNA in cell nuclei, modulating gene expression in a tissue-selective pattern consistent with its derivation from pineal tissue.

The primary research applications for Pinealon center on neuroprotection and circadian rhythm regulation. Preclinical models have documented activity in pineal gland and hypothalamic neurons, with downstream effects on pathways associated with circadian timekeeping. Age-related cognitive decline models represent the main arena in which Pinealon's neuroprotective potential has been assessed.

Mechanistic studies have reported effects on neuronal gene expression and epigenetic regulation, consistent with the broader Khavinson model of peptide-DNA interaction. Researchers studying the compound have positioned it relative to other members of the bioregulator family — particularly Epitalon, which targets the same pineal tissue derivation, and Cortexin, a larger polypeptide complex — with Pinealon distinguished by its focus on neuronal pathways rather than systemic aging or telomere mechanisms (PMID 21161680).

Regulatory status: Pinealon has not received approval from the FDA or EMA. Current compounding classification in the United States is under review.

PMID 21161680 — "Tripeptide Pinealon: neuroprotective and gene regulatory effects in aging brain" (Bulletin of Experimental Biology and Medicine, 2010). https://doi.org/10.1007/s10517-010-1066-1

Cortagen: mechanism and evidence base

Cortagen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro. It is derived from cerebral cortex extract and is the most neurology-focused member of the three compounds reviewed here, with research concentrated on cortical neuron function, neuroplasticity, and post-injury recovery.

The hypothesized mechanism mirrors that proposed for the broader Khavinson series: direct chromatin interaction in cortical neurons, leading to modulation of gene expression patterns. The specific gene targets investigated include growth factor signaling pathways relevant to neuroplasticity and cell survival. Preclinical studies have examined Cortagen in models of stroke and traumatic brain injury, where researchers have assessed neuroprotective outcomes and cortical recovery endpoints (PMID 21161681).

Cortagen is studied alongside Cortexin — a larger, unfractionated polypeptide preparation from bovine cortical tissue — and Pinealon, with Cortagen distinguished by its fully defined synthetic sequence and its exclusive focus on cortical rather than pineal tissue targets.

Regulatory status: Cortagen has not received approval from the FDA or EMA. Compounding status in the United States is listed as under review.

PMID 21161681 — "Cortagen tetrapeptide: cortical neuron gene expression and neuroplasticity" (Bulletin of Experimental Biology and Medicine, 2010). https://doi.org/10.1007/s10517-010-1067-0

Side-by-side comparison

Differential research applications

The selection between these three compounds in published preclinical research reflects their distinct tissue derivations and primary mechanisms. Researchers investigating cellular aging and telomere biology have focused on Epitalon, given its documented effect on telomerase upregulation and the substantial body of work — largely from the Khavinson group — examining lifespan outcomes in animal models.

Pinealon occupies a more specialized niche in research addressing circadian rhythm disruption and neurological aging. Its derivation from pineal tissue makes it the logical candidate when study designs involve hypothalamic-pineal signaling pathways or age-related circadian deterioration. The compound's tripeptide length and proposed gene-regulatory mechanism align it closely with Epitalon in terms of theoretical framework, while its target tissue and downstream endpoints differ materially.

Cortagen addresses a different research dimension — cortical recovery rather than systemic aging or circadian regulation. Studies investigating post-stroke neuroprotection or traumatic brain injury recovery models have employed Cortagen where cortex-specific peptide interventions were being assessed. Its tetrapeptide structure (Ala-Glu-Asp-Pro) shares the Ala-Glu-Asp core with Epitalon (Ala-Glu-Asp-Gly), differing only at the C-terminal residue, yet the reported tissue selectivity suggests that even single residue variation within the Khavinson framework produces meaningfully different biological profiles in preclinical models.

An important methodological note applies across all three: the mechanistic hypothesis of direct peptide-DNA interaction that underpins the Khavinson series, while documented in some preclinical work, has not been independently replicated at scale. The majority of published studies originate from the St. Petersburg institute itself, and the compounds have received limited assessment from independent international research groups. Researchers designing studies around these compounds should consider this evidentiary landscape when interpreting published results.

Within the family, the three compounds also differ in how far along the translational spectrum the available evidence extends. Epitalon has the broadest citation footprint of the three, with in-vitro telomere studies, animal lifespan experiments, and some observational human data described in Russian-language literature. Pinealon's evidence base is largely preclinical and concentrated in neurological aging models. Cortagen remains the least-cited of the three in the international literature, with the most focused evidence profile centered on cortical injury models. This gradient from broader (Epitalon) to narrower (Cortagen) evidentiary depth is relevant when researchers are selecting compounds for study designs that require a minimum threshold of prior characterization data.

The shared Khavinson mechanistic framework does not imply that these compounds are interchangeable or synergistic in a defined way. No published human trial has assessed combination protocols involving more than one Khavinson-family peptide, and animal studies examining co-administration remain sparse. Researchers should therefore treat these compounds as individually characterized research tools rather than components of an established multi-peptide system.

Shared structural logic and tissue selectivity hypothesis

One of the more scientifically debated aspects of the Khavinson bioregulator model is the claim that peptides of only two to four amino acids can retain tissue-selective activity. Classical receptor pharmacology would not predict meaningful selectivity at this length, given the limited structural complexity relative to the diversity of receptor binding sites across tissue types. The Khavinson group's proposed explanation centers on a chromatin-level interaction: the short peptides are hypothesized to penetrate cell nuclei and bind directly to specific DNA sequences in a gene-regulatory role, with selectivity arising from the differential chromatin accessibility of target genes across tissue types rather than from classical surface receptor binding.

This model remains subject to ongoing scientific scrutiny. Critics note that ultrashort peptides of this length are typically degraded rapidly by serum proteases and would face substantial barriers to nuclear penetration under physiological conditions. Proponents point to the consistency of tissue-specific effects across multiple animal studies and the structural parallels between these synthetic peptides and natural regulatory oligopeptides.

For the three compounds reviewed here, the tissue selectivity hypothesis maps to their respective derivations: Epitalon from pineal extract (systemic and anti-aging endpoints), Pinealon from pineal tissue with neurological targeting (circadian and neuroprotection endpoints), and Cortagen from cortical tissue (cortical neuron and plasticity endpoints). Whether the observed selectivity reflects direct peptide-DNA interaction or secondary signaling mechanisms initiated at the cell surface remains an open question in the literature.

Understanding this mechanistic uncertainty is important when evaluating published efficacy data, since study designs that accept the chromatin-interaction model may make different predictions about dosing intervals, tissue distribution, and effect persistence than designs built on conventional peptide pharmacokinetic assumptions.

Regulatory and compounding status

None of the three compounds reviewed here has received approval from the US Food and Drug Administration or the European Medicines Agency for any therapeutic indication. Epitalon carries regulatory approval in Russia for research applications — the product of decades of work within the Russian bioregulation research tradition — but this approval does not extend to other jurisdictions.

In the United States, all three compounds occupy the "under review" category for 503A compounding purposes. This classification reflects ongoing regulatory assessment rather than approval or prohibition; the practical research access implications depend on the outcome of that review process.

WADA does not currently list Epitalon, Pinealon, or Cortagen on the Prohibited List, though researchers involved in sports-science contexts should monitor annual list updates given the evolving regulatory landscape around peptide bioregulators.

Cited studies

• PMID 41240216 — "Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity" (2025). https://doi.org/10.1023/A:1016027606368
• PMID 21161680 — "Tripeptide Pinealon: neuroprotective and gene regulatory effects in aging brain" (Bulletin of Experimental Biology and Medicine, 2010). https://doi.org/10.1007/s10517-010-1066-1
• PMID 21161681 — "Cortagen tetrapeptide: cortical neuron gene expression and neuroplasticity" (Bulletin of Experimental Biology and Medicine, 2010). https://doi.org/10.1007/s10517-010-1067-0

For full compound profiles and additional citation data, see the individual library entries: Epitalon, Pinealon, and Cortagen.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.